Dedicated to the success of Scion BioMedical and the advancement of wound healing
Our Board of Directors continues to grow with professionals in healthcare, science, business and finance. This team is responsible for guiding the future growth and evolution of our organization.
Louis R. Rose, President & COO
Louis Rose serves as Scion's President of Asia Pacific, Latin America and New Innovations and is a member of Scion’s Board of Directors. He has been involved in Scion’s senior management team since June 30, 2007 and has served on the Company’s Board of Director’s since July 11, 2006. In addition to his own substantial personal investment in Scion International, which was later merged into Scion Cardio-Vascular, Mr. Rose was responsible for Scion’s initial $4MM capital raise back in April 2000. He is a skilled negotiator and strategic planner, who spearheaded the acquisition, integration and expansion of Halosource Biomedical back in 2008, which was later renamed, Scion Biomedical. This critical acquisition allowed Scion to elevate itself from a second tier distributor of chitosan topical P.A.D.’s, into a chitosan manufacturer with a platform capable of producing numerous products in the field of Wound Care. He continues to build a world class team of professionals that will contribute to Scion’s ultimate success. Prior to his work with Scion, Mr. Rose was a Wall Street executive for nearly 25 years with two major investment banking firms. In that role, he gathered and managed over $500 MM in client assets, for both individual and institutional investors. Mr. Rose co-founded Andrx Pharmaceuticals in September 1992, which became a very successful and innovative generic drug developer / manufacturer. Andrx was eventually acquired by Watson Pharmaceuticals (WPI – N.Y.S.E.) in May 2004 for over $2 Billion. Mr. Rose has served as a Board Member of several start-up companies.
Oscar Rospigliosi, CEO
Oscar Rospigliosi is a recent addition to the Scion BioMedical Board of Directors who comes to Scion with a variety of unique skill-sets directly related to the medical device industry. Mr. Rospigliosi is a senior-level executive with broad experience in domestic and international sales, marketing, financial management, strategic planning and new business development. He brings to Scion a proven track record of successfully delivering and implementing profitable improvements and quality in medical device manufacturing both domestically and internationally. Mr. Rospigliosi has vast in-depth knowledge of international regulatory requirements for both manufacturing and management processes.
From 2000 – 2004 Mr. Rospigliosi was the Director of Operations for Comesa Poland, a leading distributor in Poland in the fields of in-vitro diagnostics, life sciences, orthopedics and interventional products. Comesa Poland is a subsidiary of the Werfen Group.
From 2005 – 2013, Mr. Rospigliosi was the CEO of Bolton Medical Group where he guided this small company with just $4.5M in annual revenue and under 10 employees to a $35M in annual revenues and a sales team of 25 sales reps with an emphasis in the cardio-thoracic market. With the introduction of a unique abdominal stent graft product line, Mr. Rospigliosi was able to drive sales to over $50M with greater than 10% growth year over year. As Bolton’s CEO, Mr. Rospigliosi, was responsible for overseeing worldwide distribution which included Asia, The European Union and all of Latin America. He put together a comprehensive Business Plan for Bolton Medical to reach $100M in revenue by 2016. By the time Mr. Rospigliosi left Bolton Medical, sales exceeded $80M.
From April 2014 – December 2015, Mr. Rospigliosi was Partner at the Newport Board Group in South Florida providing CEO and advisory services to emerging middle market companies, in various stages of development. It was here that Mr. Rospigliosi became acquainted with Scion BioMedical, Inc. and agreed to join its Board of Directors. Mr. Rospigliosi is fluent in 5 languages including: Spanish, English, French, Italian & Polish.
Peter Gurman, Board Director
Mr. Gurman brings more than 25 years of investment banking experience to Scion’s Board of Directors. He formerly served as First Vice President at Morgan Stanley Investment Management Services from 1986 until 2002 where he was responsible for over $1 Billion in Taft-Hartley assets. Prior to joining Morgan Stanley, Mr. Gurman consulted with SEI Corporation. Mr. Gurman graduated from Wichita State University with a Bachelors of Business Administration degree and from the University of Arizona with a Masters of Science in Rehabilitation Counseling Degree.